Brain Metastasis Management Varies Among Oncologists

Share this content:
Practice patterns for the management of patients with more than 3 brain metastases appear to vary widely among radiation oncologists.
Practice patterns for the management of patients with more than 3 brain metastases appear to vary widely among radiation oncologists.

Practice patterns for the management of patients with more than 3 brain metastases appear to vary widely among radiation oncologists, according to a study published in Cancer.1

Published guidelines established the optimal treatment strategies for patients with up to 3 to 4 brain metastases, but with stereotactic radiosurgery (SRS) delivery techniques improving, use of SRS for those with more than 3 metastases is increasing.

For this study, researchers surveyed more than 5000 practicing radiation oncologists, of which 711 responded. Questions included the ideal cutoff number at which clinicians would switch from using SRS to whole-brain radiotherapy and which group of patients presents the greatest challenge.

Specialists in treating central nervous system (CNS) tumors were more likely to treat patients with brain metastases with SRS, though there was a significant difference of opinion in the optimal cut-off for the number of lesions to treat with SRS instead of whole-brain radiotherapy.

CNS specialists who saw 10 or more patients per month were more likely to reserve SRS for patients with about 8 lesions, while CNS specialists treating 5 to 9 patients per month and non-CNS specialists used SRS for patients with 5 to 6 brain lesions.

More than half of radiation oncologists said that patients with 4 to 6 brain metastases are the most challenging subpopulation to treat, suggesting that clinicians struggle with treating patients with a moderate intracranial disease burden.

RELATED: Brainstem Gliomas

The findings demonstrate that radiation oncologists, particularly high-volume CNS specialists, are treating significantly more brain metastases with SRS than what is recommended by consensus guidelines. Further prospective studies are warranted to confirm the practice patterns observed in this study.

Reference

  1. Sandler KA, Shaverdian N, Cook RR, et al. Treatment trends for patients with brain metastases: Does practice reflect the data? Cancer. 2017 Feb 8. doi: 10.1002/cncr.30607 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters